

## **Certificate of Analysis**

<b>Cell Count</b>	1.75 Million per vial
<b>Viability</b>	95.1%
<b>CD8+</b>	91.45%
<b>CD8+ Neg Tetramer+</b>	8.43%
<b>CD8+ MART-1 Tetramer+</b>	99.73%
<b>Sterility Testing</b>	Negative for bacteria and fungi

## **Donor Information**



<b>Donor ID</b>	398
<b>Gender</b>	41
<b>Age</b>	Female
<b>Race</b>	Caucasian
<b>Height</b>	5'6"
<b>Weight</b>	142 lbs
<b>ABO Type</b>	A positive

## **HLA Typing**

	<b>Allele 1</b>	<b>Allele 2</b>
<b>HLA-A</b>	0201	0301
<b>HLA-B</b>	0702	3901
<b>HLA-C</b>	0702	0702
<b>HLA-DRB1</b>	0801	1501


Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures.

**FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**



Negative tetramer = HLA-A\*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA); MART-1 tetramer = MART-126-35 A27L peptide (ELAGIGILTV)/ HLA-A\*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA)

### IFN-gamma Secretion



20,000 T cells were plated in a 96-well round-bottom plate alone or in the presence of 20,000 T2 cells, a B-LCL expressing HLA-A\*0201) alone or in the presence of increasing concentrations of HLA-A\*0201 restricted irrelevant control MART-1 26-35 A27L peptide (ELAGIGILTV) or HLA-A\*0201 restricted WT-1 peptide (RMFPNAPYL). Culture media used is RPMI 1640 and 10% FBS. After an overnight (18-24h) incubation period, supernatant was collected from each well. IFN-g concentration was analyzed using the Meso Scale Discovery IFN-g assay.

**FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**